Q4 2024 Management View CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion ...
Jefferies analyst Akash Tewari maintained a Buy rating on Exelixis (EXEL – Research Report) today and set a price target of $42.00. Akash Tewari’s rating is based on a combination of factors ...
Hosted on MSN19d
Truist raises Exelixis stock target to $43 on Zanza optimismThe adjustment comes after encouraging data from a Phase 1 study, STELLAR-001, which has bolstered confidence in the potential success of the company's Phase 3 study for its drug Zanza in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results